NTRA News and Press, Natera Inc. From 03/02/23

Pan-cancer policy from Blue Shield of California covers adjuvant, recurrence monitoring, and treatment monitoring Multi-cancer policy from BCBS of Louisiana covers CRC, Bladder, and IO monitoring Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today an...

Natera, Inc. (NTRA) Q4 2022 Results Conference Call February 28, 2022 4:30 PM ET Company Participants Steven Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Solomon Moshkevich - GM, Oncology John Fesko - Chief Business Officer Confe...

Natera press release ( NASDAQ: NTRA ): Q4 GAAP EPS of -$1.37 beats by $0.05 . Revenue of $217.3M (+25.6% Y/Y) beats by $1.8M . At December 31, 2022, Natera held approximately $898.4 million in cash, cash equivalents, short-term investments and restricted cash, compared...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided an update on recent business progress and financial outlook. Recent Accomplishments & Highlights Generated...

Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company&#x...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2022, after the market close on Feb. 28, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT...

Natera ( NASDAQ: NTRA ) shares surged ~18% to reach a five-month high on Thursday after the diagnostics company announced its Signatera cancer test had met Medicare coverage criteria for breast cancer screening. The decision by the Molecular Diagnostics Services Program (MolDX) of...

Coverage to include serial monitoring in all subtypes, including hormone receptor-positive, HER2-positive, and triple negative breast cancers Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Cen...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the publication of a new paper in Pediatric Nephrology , which highlights the clinical utility of Renasight™ in aiding the diagnosis and management of kidney disease. The publication can be found ...

Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...